Champions Oncology (CSBR) Fundamentals 2026 — Revenue Analysis | SniperIQ
Champions Oncology (CSBR) is a US-listed Healthcare company in Biotechnology with a market capitalization of $83M, trading at $5.96 on the NASDAQ. This SniperIQ fundamentals page covers Champions Oncology's valuation, profitability (net margin -3.9%), revenue ($57M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Champions Oncology's market cap?
Champions Oncology (CSBR) has a market capitalization of approximately $83M, trading at $5.96 on the NASDAQ. Market cap moves with the live share price.
What is Champions Oncology's P/E ratio?
Champions Oncology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 19.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Champions Oncology?
Champions Oncology runs a net profit margin of -3.9%, a gross margin of 45.9%, and an operating margin of -3.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Champions Oncology generate?
Champions Oncology reported revenue of $57M for fiscal year 2025, with net income of $5M and earnings per share (EPS) of 0.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Champions Oncology pay a dividend?
Champions Oncology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Champions Oncology financially healthy?
Champions Oncology carries a debt-to-equity ratio of 1.17x and a current ratio of 0.98x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Champions Oncology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Champions Oncology (CSBR) the key facts are: market cap $83M, revenue $57M, 52-week range 5.5-8.74. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Champions Oncology's full fundamentals live
Get Champions Oncology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.